Comment
detect increased numbers of exacerbations overall, but of lesser severity and with fewer days spent in hospital, as a result of vigilant early treatment. Additionally, improvement in symptom awareness does not necessarily result in adequate detection of exacerbations, since non-pulmonary symptoms are often misinterpreted as pulmonary alarm symptoms, and vice versa.12 In summary, interventions to enhance selfmanagement in patients with COPD are very diverse and lead to conflicting outcomes. Self-management seems not to be suitable for everyone, but when hands-on guidance is provided (by a case manager, or a dedicated spouse, friend, or family member), it can be successful in a subgroup of up to 40% of patients. This finding should be further investigated in large, carefully designed studies. Furthermore, reports of future studies should describe precisely the nature of the intervention, including the intensity and frequency of contact with a case manager, to allow valid comparisons across different programmes. In this way, guidelines could be formulated for health-care providers on the best way to deliver self-management to patients with COPD. *Annemarije L Kruis, Onno CP van Schayck, Johannes CCM in ’t Veen, Thys van der Molen, Niels H Chavannes Department of Public Health and Primary Care, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Netherlands (ALK, NHC); Department of General Practice, University of Maastricht, Research Institute CAPHRI, Maastricht, Netherlands (OCPvS); Department of Pulmonary Diseases, Sint Franciscus Gasthuis, Rotterdam, Netherlands (JCCMi’tV); and Department of General Practice and Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen, Netherlands (TvdM) [email protected]
JCCMi’tV has had temporary consulting roles on the advisory boards of AstraZeneca, Novartis, and Chiesi. NHC has had temporary consulting roles on the advisory boards of Novartis, Chiesi, Boehringer Ingelheim, and Pfizer. OCPvS has received unrestricted research grants from Pfizer and Boehringer Ingelheim. NHC and OCPvS have had temporary consulting roles on the advisory board of Patient Empowerment. This programme is a cooperative venture between the Dutch Asthma Foundation, the health insurance company Achmea, and AstraZeneca to improve the position of patients with chronic obstructive pulmonary disease in the care process by means of shared decision making and patient empowerment. ALK and TvdM declare that they have no conflicts of interests. 1
2
3
4
5 6
7
8
9
10
11
12
Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163: 585–91. Rice KL, Dewan N, Bloomfield HE, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2010; 182: 890–96. Koff PB, Jones RH, Cashman JM, Voelkel NF, Vandivier RW. Proactive integrated care improves quality of life in patients with COPD. Eur Respir J 2009; 33: 1031–38. Bischoff EWMA, Akkermans R, Bourbeau J, van Weel C, Vercoulen JH, Schermer TRJ. Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial. BMJ 2012; 345: e7642. Bischoff EW, Hamd DH, Sedeno M, et al. Effects of written action plan adherence on COPD exacerbation recovery. Thorax 2011; 66: 26–31. Trappenburg JC, Monninkhof EM, Bourbeau J, et al. Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicentre randomised controlled trial. Thorax 2011; 66: 977–84. Bucknall CE, Miller G, Lloyd SM, et al. Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ 2012; 344: e1060. Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med 2012; 156: 673–83. In ‘t Veen JCCM, Mennema B, van Noort E. Online self-management in COPD or asthma: with or without the healthcare provider? Eur Respir J 2012; 40 (suppl 56): 237s. Vandivier RW, Linderman DJ, Koff PB. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations. Ann Intern Med 2012; 157: 530–31. Koff PB, Min S, Freitag TJ, et al. Proactive integrated care reduces critical care & improves quality-of-life in COPD. American Thoracic Society 2009 International Conference; San Diego, CA, USA; May 15–20, 2009; A3100. Main J, Moss-Morris R, Booth R, Kaptein AA, Kolbe J. The use of reliever medication in asthma: the role of negative mood and symptom reports. J Asthma 2003; 40: 357–65.
Respiratory medicine and critical care: a call for papers Published Online October 22, 2013 http://dx.doi.org/10.1016/ S2213-2600(13)70228-5 For Global Burden of Disease Study 2010 see http://www. thelancet.com/themed/globalburden-of-disease
672
The latest statistics from the Global Burden of Disease Study 2010 and, more recently, from the European Respiratory Society’s European Lung White Book, have highlighted respiratory diseases as a key concern for global health and future sustainability. A depressing picture has been painted by these and other studies with horrifying numbers projected for the future—however, respiratory research and treatment has never been a
more active arena. Much progress has been made in recent years with new treatments reported for both common and rare respiratory diseases, improvements in treatment delivery and compliance, and increased understanding of the progenitors and risk factors for respiratory diseases. The Lancet and The Lancet Respiratory Medicine would like to hear from authors of this thriving research www.thelancet.com/respiratory Vol 1 November 2013
Comment
community as the two journals are once again planning special issues timed to the 2014 American Thoracic Society (ATS) conference, in San Diego, CA, USA, on May 16–21, to highlight this important area of medicine. We welcome high-quality submissions in any area of clinical research related to respiratory medicine and critical care, particularly clinical trials and research that will change clinical practice or current thinking. The Lancet group is dedicated to the furtherance of respiratory and critical care medicine, as proven by recent practice-changing publications and the launch earlier this year of The Lancet Respiratory Medicine. This specialty journal is able to replicate the publication experience of The Lancet with the same fast-track process for original research, in which papers can be published online within 4–8 weeks from submission. The Lancet group is well known as a global brand with an innovative website that can highlight papers alongside author podcasts and make sure your
www.thelancet.com/respiratory Vol 1 November 2013
papers reach a wide audience. Both journals share a dedicated assistant editor team who subedit papers after acceptance and thoroughly check data, figures, and tables. All Lancet journals also benefit from having a team of inhouse illustrators and production editors who can redraw figures and help to ensure the data are presented clearly. Please submit your paper via our e-submission system mentioning this call for papers in your covering letter. If you are presenting your research at the ATS meeting, we can time publication to your presentation. The deadline for submissions is Jan 31, 2014. We look forward to reading your research that will change the future landscape of respiratory diseases.
For European Lung White Book see http://www.erswhitebook. org/ To submit a paper go to http:// ees.elsevier.com/thelancetrm/ or http://ees.elsevier.com/ thelancet/
*Emma Grainger, Sabine Kleinert The Lancet Respiratory Medicine, London NW1 7BY, UK (EG); and The Lancet, London, UK (SK) [email protected]
673
detect increased numbers of exacerbations overall, but of lesser severity and with fewer days spent in hospital, as a result of vigilant early treatment. Additionally, improvement in symptom awareness does not necessarily result in adequate detection of exacerbations, since non-pulmonary symptoms are often misinterpreted as pulmonary alarm symptoms, and vice versa.12 In summary, interventions to enhance selfmanagement in patients with COPD are very diverse and lead to conflicting outcomes. Self-management seems not to be suitable for everyone, but when hands-on guidance is provided (by a case manager, or a dedicated spouse, friend, or family member), it can be successful in a subgroup of up to 40% of patients. This finding should be further investigated in large, carefully designed studies. Furthermore, reports of future studies should describe precisely the nature of the intervention, including the intensity and frequency of contact with a case manager, to allow valid comparisons across different programmes. In this way, guidelines could be formulated for health-care providers on the best way to deliver self-management to patients with COPD. *Annemarije L Kruis, Onno CP van Schayck, Johannes CCM in ’t Veen, Thys van der Molen, Niels H Chavannes Department of Public Health and Primary Care, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Netherlands (ALK, NHC); Department of General Practice, University of Maastricht, Research Institute CAPHRI, Maastricht, Netherlands (OCPvS); Department of Pulmonary Diseases, Sint Franciscus Gasthuis, Rotterdam, Netherlands (JCCMi’tV); and Department of General Practice and Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen, Netherlands (TvdM) [email protected]
JCCMi’tV has had temporary consulting roles on the advisory boards of AstraZeneca, Novartis, and Chiesi. NHC has had temporary consulting roles on the advisory boards of Novartis, Chiesi, Boehringer Ingelheim, and Pfizer. OCPvS has received unrestricted research grants from Pfizer and Boehringer Ingelheim. NHC and OCPvS have had temporary consulting roles on the advisory board of Patient Empowerment. This programme is a cooperative venture between the Dutch Asthma Foundation, the health insurance company Achmea, and AstraZeneca to improve the position of patients with chronic obstructive pulmonary disease in the care process by means of shared decision making and patient empowerment. ALK and TvdM declare that they have no conflicts of interests. 1
2
3
4
5 6
7
8
9
10
11
12
Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163: 585–91. Rice KL, Dewan N, Bloomfield HE, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2010; 182: 890–96. Koff PB, Jones RH, Cashman JM, Voelkel NF, Vandivier RW. Proactive integrated care improves quality of life in patients with COPD. Eur Respir J 2009; 33: 1031–38. Bischoff EWMA, Akkermans R, Bourbeau J, van Weel C, Vercoulen JH, Schermer TRJ. Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial. BMJ 2012; 345: e7642. Bischoff EW, Hamd DH, Sedeno M, et al. Effects of written action plan adherence on COPD exacerbation recovery. Thorax 2011; 66: 26–31. Trappenburg JC, Monninkhof EM, Bourbeau J, et al. Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicentre randomised controlled trial. Thorax 2011; 66: 977–84. Bucknall CE, Miller G, Lloyd SM, et al. Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ 2012; 344: e1060. Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med 2012; 156: 673–83. In ‘t Veen JCCM, Mennema B, van Noort E. Online self-management in COPD or asthma: with or without the healthcare provider? Eur Respir J 2012; 40 (suppl 56): 237s. Vandivier RW, Linderman DJ, Koff PB. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations. Ann Intern Med 2012; 157: 530–31. Koff PB, Min S, Freitag TJ, et al. Proactive integrated care reduces critical care & improves quality-of-life in COPD. American Thoracic Society 2009 International Conference; San Diego, CA, USA; May 15–20, 2009; A3100. Main J, Moss-Morris R, Booth R, Kaptein AA, Kolbe J. The use of reliever medication in asthma: the role of negative mood and symptom reports. J Asthma 2003; 40: 357–65.
Respiratory medicine and critical care: a call for papers Published Online October 22, 2013 http://dx.doi.org/10.1016/ S2213-2600(13)70228-5 For Global Burden of Disease Study 2010 see http://www. thelancet.com/themed/globalburden-of-disease
672
The latest statistics from the Global Burden of Disease Study 2010 and, more recently, from the European Respiratory Society’s European Lung White Book, have highlighted respiratory diseases as a key concern for global health and future sustainability. A depressing picture has been painted by these and other studies with horrifying numbers projected for the future—however, respiratory research and treatment has never been a
more active arena. Much progress has been made in recent years with new treatments reported for both common and rare respiratory diseases, improvements in treatment delivery and compliance, and increased understanding of the progenitors and risk factors for respiratory diseases. The Lancet and The Lancet Respiratory Medicine would like to hear from authors of this thriving research www.thelancet.com/respiratory Vol 1 November 2013
Comment
community as the two journals are once again planning special issues timed to the 2014 American Thoracic Society (ATS) conference, in San Diego, CA, USA, on May 16–21, to highlight this important area of medicine. We welcome high-quality submissions in any area of clinical research related to respiratory medicine and critical care, particularly clinical trials and research that will change clinical practice or current thinking. The Lancet group is dedicated to the furtherance of respiratory and critical care medicine, as proven by recent practice-changing publications and the launch earlier this year of The Lancet Respiratory Medicine. This specialty journal is able to replicate the publication experience of The Lancet with the same fast-track process for original research, in which papers can be published online within 4–8 weeks from submission. The Lancet group is well known as a global brand with an innovative website that can highlight papers alongside author podcasts and make sure your
www.thelancet.com/respiratory Vol 1 November 2013
papers reach a wide audience. Both journals share a dedicated assistant editor team who subedit papers after acceptance and thoroughly check data, figures, and tables. All Lancet journals also benefit from having a team of inhouse illustrators and production editors who can redraw figures and help to ensure the data are presented clearly. Please submit your paper via our e-submission system mentioning this call for papers in your covering letter. If you are presenting your research at the ATS meeting, we can time publication to your presentation. The deadline for submissions is Jan 31, 2014. We look forward to reading your research that will change the future landscape of respiratory diseases.
For European Lung White Book see http://www.erswhitebook. org/ To submit a paper go to http:// ees.elsevier.com/thelancetrm/ or http://ees.elsevier.com/ thelancet/
*Emma Grainger, Sabine Kleinert The Lancet Respiratory Medicine, London NW1 7BY, UK (EG); and The Lancet, London, UK (SK) [email protected]
673
